logo
The Steering Committee
Alastair Carruthers, MD, FRCP(C)
You need to upgrade your Flash Player
You need to upgrade your Flash Player to view this content.

What's New

Interactive case study on volumizing with dermal fillers available now!
Our newest case study, developed with Steering Committee Member Mark L. Jewell, MD, explores treatment options for the off-label use of dermal fillers for mid-face volumizing. Upon completion of the case study, posttest, and evaluation form, you'll receive 1.0 AMA PRA Category 1 Credit instantly!

New CME Webinar!
Current Concepts in Facial Aesthetics: Consensus Recommendations for Botulinum Toxin Type A (BoNTA) and Hyaluronic Acid (HA) Fillers is a CME Webinar archive featuring Drs Steven Fagien, Steven Dayan, and Jessica Wu. Presentations focus on best practices for BoNTA and HA Fillers used alone and in combination for the upper, middle, and lower face.

Ask The Expert
Steering Committee Member Sue Ellen Cox, MD, addresses questions regarding appropriate management of a widened nasal root area following administration of botulinum toxin type A (BoNTA), appropriate dosing to ensure long-lasting duration of BoNTA, treatment options for severe hyperhidrosis of the feet, and more!

Updated Product Information page!
This comprehensive resource provides information on product indications and contraindications, and adverse events for botulinum toxins, dermal fillers, and topical creams used in aesthetic-enhancement procedures. Links to labeling information, US FDA advisories, and commentaries from our Steering Committee are also featured!

Clinical Literature Overviews
Our latest current literature entries explore the use of calcium hydroxylapatite microspheres and poly-L-lactic acid for HIV-associated facial lipoatrophy, combination energy-based treatment for photodamaged skin, and energy-based devices to address solar lentigines. Also featured: Expert commentary from Steering Committee Member Sue Ellen Cox, MD.

Slides of the Month

 

In The News

Winston Pharmaceuticals, Inc. Receives Orphan Drug Designation For Novel Patch To Treat Post-Herpetic Neuralgia
Feb 26, 2009 -- Winston Pharmaceuticals, Inc. (OTC BB: WPHM) today announced that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for its lead compound, Civamide, a novel TRPV-1 receptor modulator, being developed as a dermal patch for the treatment of post-herpetic neuralgia. Winston recently released results of a Phase I study demonstrating the patch's ease of use with repeated 24-hour applications.
Non-Profit Gives $800,000 For Melanoma Research In 2009
Feb 25, 2009 -- Today the Melanoma Research Foundation (MRF), the largest independent, national organization devoted to melanoma in the U.S., announced the recipients of five new research grants as part of its Career Development Grant Program and Established Investigator Grant Program.
CHMP Delays European Commission Decision Process To Approve ZEVTERATM
Feb 24, 2009 -- Janssen-Cilag announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on ZEVTERATM (ceftobiprole medocaril) pending completion of a Good Clinical Practice (GCP) inspection. ZEVTERA is in the final stage of approval for the treatment of complicated skin and soft tissue infections.
CHMP Delays European Commission Decision Process To Approve ZEVTERATM
Feb 24, 2009 -- Janssen-Cilag announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has decided to delay the European Commission decision process on ZEVTERATM (ceftobiprole medocaril) pending completion of a Good Clinical Practice (GCP) inspection. ZEVTERA is in the final stage of approval for the treatment of complicated skin and soft tissue infections.
Copyright 2007 Medical News Today
Login
Username:
Password:
Register
Forgot Password?
Ask the Expert
Have a question for one of our experts?
Submit it here

View all Questions

Participate in our
Online polls
What is the biggest challenge that you face in your practice in dealing with patients seeking aesthetic enhancement?






Upcoming Events